Valuation : Actinium Pharmaceuticals, Inc.

Market Cap 44.02M 37.93M 35.91M 32.55M 61.06M 4.21B 61.37M 427M 164M 2.14B 165M 162M 6.76B P/E 2026 *
10x
P/E 2027 * -2.07x
Enterprise Value 44.02M 37.93M 35.91M 32.55M 61.06M 4.21B 61.37M 427M 164M 2.14B 165M 162M 6.76B EV / Sales 2026 *
3.77x
EV / Sales 2027 * -
Free-Float
91.34%
Yield 2026 *
-
Yield 2027 * -
15/08 Actinium Pharmaceuticals Expands Manufacturing Capacity for Actimab-A Program CI
15/08 Actinium Pharmaceuticals, Inc. Amends Its Investigational New Drug CI
08/08 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
03/06 Actinium Pharmaceuticals Presents New Data on Atnm-400 Demonstrating Potent Activity in Prostate Cancer Models Resistant to All Three Approved Androgen Receptor Inhibitors CI
01/06 Actinium Pharmaceuticals, Inc. Appoints Steffen Heeger as Chief Medical Officer CI
01/06 Actinium Pharmaceuticals Presents New Radiochemistry Data Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates CI
30/05 Actinium Pharmaceuticals - receives two Canadian patent allowances for Actimab-A and Iomab-Act programs RE
30/05 Actinium Pharmaceuticals Receives Patent Allowances for Actimab-A and Iomab-Act Programs in Canada CI
09/05 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
06/05 Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of Atnm-400 Across Lung and Prostate Cancer and Radioconjugate Optimization CI
23/04 Actinium Pharmaceuticals, Inc. Highlights Transcriptional Reprogramming As Key Mechanism Underpinning Mutation-Agnostic Activity Of Actimab-A In AML CI
23/04 Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models At the 2026 American Association of Cancer Research Annual Meeting CI
07/04 Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for Atnm-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in Aml CI
1 day+6.87%
1 week+35.92%
Current month+37.25%
1 month+76.52%
3 months+34.62%
6 months+18.64%
Current year+2.94%
1 week 1.06
Extreme 1.06
1.42
1 month 0.85
Extreme 0.8451
1.42
Current year 0.74
Extreme 0.735101
1.53
1 year 0.74
Extreme 0.735101
1.74
3 years 0.74
Extreme 0.735101
10.24
5 years 0.74
Extreme 0.735101
15.12
10 years 0.74
Extreme 0.735101
64.5
Manager TitleAgeSince
Chief Executive Officer 62 09/06/2017
Chief Tech/Sci/R&D Officer - 01/06/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 71 01/01/2008
Chairman 62 01/10/2013
Director/Board Member 68 08/11/2013
Date Insider Type Main position Quantity % Market Cap. Importance
3/9/26 Other

Chief Technology Officer

333,648 1.0634%
3/9/26 Other

Chief Technology Officer

403,868 1.2872%
2/9/26 Free

Director

157,000 0.5004%
Change 5-day change 1-year change 3-year change Capi.($)
+6.87%+35.92%-16.67%-80.98% 44.02M
-2.11%-1.68%+44.52%+95.15% 66.93B
-0.23%-4.45%+30.39%+73.64% 61.97B
+1.67%+2.47%-11.23%+388.34% 28.27B
-1.05%-4.43%+30.56%+10.07% 24.59B
+0.34%-6.78%-7.27%-17.99% 24.3B
+0.43%-3.37%+14.85%-19.29% 19.41B
-3.03%-2.29%+185.12%+334.07% 16.77B
-1.94%-4.94%-5.29%+495.65% 14.18B
-2.28%-4.90%+43.64%+155.21% 13.91B
Average -0.13%+0.48%+30.86%+143.39% 27.04B
Weighted average by Cap. -0.84%-3.06%+33.45%+133.63%

Financials

2026 *2027 *
Net sales 11.67M 10.05M 9.52M 8.63M 16.18M 1.11B 16.27M 113M 43.47M 567M 43.82M 42.85M 1.79B -
Net income 4.91M 4.23M 4M 3.63M 6.81M 469M 6.84M 47.54M 18.28M 238M 18.43M 18.02M 754M -31.71M -27.32M -25.87M -23.45M -43.99M -3.03B -44.21M -307M -118M -1.54B -119M -116M -4.87B
Net Debt - -
Logo Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.
Employees
27
Date Price Change Volume
11/09/26 USD 1.400 +6.87% 242,659
10/09/26 USD 1.310 +6.50% 226,758
09/09/26 USD 1.230 0.00% 366,566
08/09/26 USD 1.230 +19.42% 574,177
04/09/26 USD 1.030 -1.90% 54,229
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.400USD
Average target price
3.500USD
Spread / Average Target
+150.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATNM Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!